© 2023 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
January 27, 2023
Elacestrant has recieved FDA approval for the treatment of patients with estrogen receptor-positive/HER2-negative advanced or metastatic breast cancer.
January 26, 2023
Results from the CRC-PREVENT trial of a noninvasive diagnostic screening test have led to the submission of a premarket approval application to the FDA for patients with colorectal cancer and advanced adenomas.
January 20, 2023
Better health-related quality of life outcomes were seen with tislelizumab vs sorafenib in patients with hepatocelluar carcinoma.
January 12, 2023
A phase 1 trial showed efficacy of a novel T-cell therapy targeting MAGE-A4 in solid tumors, particularly synovial sarcoma.
January 09, 2023
A phase 2 dose expansion cohort which received the investigational agent abequolixron plus docetaxel showed clinical responses in patients with non–small cell lung cancer and small cell lung cancer.
January 06, 2023
Positive topline results were announced from a study comparing TAVT-45, a formulation of abiraterone acetate that is easier to swallow, to the current formulation.